TG Therapeutics, Inc.
TGTX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -3.64 | 0.09 | -4.99 |
| FCF Yield | 0.14% | -0.50% | -0.59% | -0.36% |
| EV / EBITDA | 143.63 | 480.90 | 138.70 | 228.60 |
| Quality | ||||
| ROIC | 5.96% | 1.60% | 5.62% | 2.44% |
| Gross Margin | 86.58% | 87.14% | 85.77% | 88.86% |
| Cash Conversion Ratio | 0.26 | -5.67 | -1.10 | -3.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 40.99% | 166.27% | 255.90% | 390.73% |
| Free Cash Flow Growth | 125.73% | -11.99% | -109.85% | -320.90% |
| Safety | ||||
| Net Debt / EBITDA | 3.31 | 9.97 | 2.32 | 3.84 |
| Interest Coverage | 5.19 | 1.28 | 4.24 | 1.15 |
| Efficiency | ||||
| Inventory Turnover | 0.12 | 0.10 | 0.14 | 0.11 |
| Cash Conversion Cycle | 248.28 | 279.57 | 412.33 | -37.10 |